



Docket No. 21327-0701 US2

Certificate of Mailing/Transmission (37 C.F.R. § 1.8(a)):

[X] Pursuant to 37 C.F.R. § 1.8, I hereby certify that this paper and all enclosures are being deposited with the United States Postal Service as first class mail on the date indicated below in an envelope addressed to the Assistant Commissioner for Patents, Washington D.C. 20231.

[] Pursuant to 37 C.F.R. § 1.6(d), I hereby certify that this paper and all enclosures are being sent via facsimile on the date indicated below to the attention of Examiner _____ at Facsimile No. _____ at _____ a.m./p.m.

Dated: Nov. 19, 2002Name of Person Certifying:
Printed Name:Nancy Hine
Nancy Hine#12/
K.T.
12/4
ELECT.
w/EDT
(3)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

DEC 02 2002

TECH CENTER 1600/2900

Applicant: Gill et al. Assignee: Not Assigned
Serial No.: 09/805,761 Examiner: Sean McGarry
Filing Date: March 13, 2001 Group Art Unit: 1635
Title: **METHOD AND COMPOSITIONS FOR ANTISENSE VEGF OLIGONUCLEOTIDES**

Assistant Commissioner for Patents
Washington, D.C. 20231

RESPONSE TO RESTRICTION REQUIREMENT UNDER 35 U.S.C. § 121

Dear Sir:

This is in response to the Office Action dated August 6, 2002 ("Office Action" or "Paper 10"). Accordingly this response is timely filed upon payment of a fee for a 3-month extension of time.

In the Restriction Requirement dated August 6, 2002, the Examiner stated that there were distinct inventions and required Applicants to elect one invention for prosecution on the merits. The groups set forth in the Restriction Requirement are as follows:

- I. Claims 1-14, drawn to a VEGF antisense and method of inhibiting cancer cell proliferation therewith, classifiable in class 514, subclass 44.
- II. Claims 15-17, drawn to a method of assessing the therapeutic potential of a candidate agent to inhibit cancer cell proliferation via contacting cells exhibiting autocrine growth activity with a candidate compound and detecting VEGF expression, classifiable in class 435, subclass 4.
- III. Claim 18, drawn to prognostic assay for a subject afflicted with a disease comprising detecting in a sample VEGF receptor expression, classifiable in class 435, subclass 7.1.

Office Action at 2.

11/27/2002 MAHME1 00000028 501193 09805761
01 FC:2253 460.00 CH